Quarterly Report Q2 2016

April 16, 2018

Prometic reports second quarter 2016 highlights and financial results

 

  • PBI-4050 clinical efficacy further evidenced in metabolic syndrome and type 2 diabetes patients
  •  Plasminogen FDA fast track designation secured, clinical efficacy further evidenced in plasminogen deficient patients
  • Strengthened balance sheet with closing of $60.1 million bought deal equity financing
  • H1 2016 revenues of $8.5 million vs. $4.8 million for H1 2015
Previous Flipbook
Quarterly Report Q3 2016
Quarterly Report Q3 2016

Prometic reports third quarter 2016 highlights and financial results

Next Flipbook
Quarterly Report Q1 2016
Quarterly Report Q1 2016

Prometic reports its first quarter 2016 highlights and financial results